COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementArslan (RCT)92%0.08 [0.01-0.79]cases1/719/42CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP92%0.08 [0.01-0.79]1/719/4292% improvementAll studies76%0.24 [0.07-0.79]2/22023/53476% improvement4 quercetin COVID-19 studiesc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.35Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementAll studies58%0.42 [0.09-1.82]1/14914/49258% improvement3 quercetin COVID-19 mortality resultsc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.16Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)94%0.06 [0.00-1.00]0/768/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.02-1.05]0/979/9787% improvementOnal (RCT)94%0.06 [0.00-0.98]0/5214/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment94%0.06 [0.00-0.98]0/5214/39594% improvementAll studies90%0.10 [0.02-0.52]0/14923/49290% improvement3 quercetin COVID-19 ICU resultsc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.72Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)68%0.32 [0.14-0.70]hosp.7/7622/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]hosp.0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment68%0.32 [0.15-0.69]7/9723/9768% improvementAll studies68%0.32 [0.15-0.69]7/9723/9768% improvement2 quercetin COVID-19 hospitalization resultsc19quercetin.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.93Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementAll studies58%0.42 [0.09-1.82]1/14914/49258% improvement3 quercetin COVID-19 serious outcomesc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.16Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Arslan (RCT)92%0.08 [0.01-0.79]1/719/42CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP92%0.08 [0.01-0.79]1/719/4292% improvementAll studies92%0.08 [0.01-0.63]1/719/4292% improvement1 quercetin COVID-19 case resultc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.40Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)74%0.26 [0.12-0.57]5/2119/21Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment74%0.26 [0.12-0.57]5/2119/2174% improvementAll studies74%0.26 [0.12-0.57]5/2119/2174% improvement1 quercetin COVID-19 viral clearance resultc19quercetin.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.37Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementArslan (RCT)92%0.08 [0.01-0.79]cases1/719/42CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP92%0.08 [0.01-0.79]1/719/4292% improvementAll studies76%0.24 [0.07-0.79]2/22023/53476% improvement4 quercetin COVID-19 Randomized Controlled Trialsc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.35Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementAll studies58%0.42 [0.09-1.82]1/14914/49258% improvement3 quercetin COVID-19 RCT mortality resultsc19quercetin.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.16Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementAll studies79%0.21 [0.02-1.82]0/974/9779% improvement2 quercetin COVID-19 peer reviewed trialsc19quercetin.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.41Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)94%0.06 [0.00-1.00]ICU0/768/76Di Pierro (RCT)68%0.32 [0.14-0.70]hosp.7/7622/76Di Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Di Pierro (RCT)67%0.33 [0.01-7.74]ICU0/211/21Di Pierro (RCT)67%0.33 [0.01-7.74]hosp.0/211/21Di Pierro (RCT)74%0.26 [0.12-0.57]viral+5/2119/21Di Pierro (RCT)89%0.11 [0.01-1.94]viral+0/214/21Onal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Onal (RCT)94%0.06 [0.00-0.98]ICU0/5214/395CT​1Onal (RCT)68%0.32 [0.04-2.29]no disch.1/5224/395CT​1Arslan (RCT)92%0.08 [0.01-0.79]cases1/719/42CT​1quercetin COVID-19 outcomesc19quercetin.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home